674819-27-3

Basic information

• Product Name: Cyclohexanecarboxylic acid, 4-[[[(4-bromophenyl)sulfonyl]amino]methyl]-, trans-
• CAS NO: 674819-27-3
• Molecular Formula: C14H18BrNO4S
• Molecular Weight: 376.271
• Mol File: 674819-27-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarboxylic acid, 4-[[[(4-bromophenyl)sulfonyl]amino]methyl]-, trans-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 4-[[[(4-bromophenyl)sulfonyl]amino]methyl]-, trans-(674819-27-3)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 4-[[[(4-bromophenyl)sulfonyl]amino]methyl]-, trans-(674819-27-3)

Safety Data

• Hazardous Substances Data: 674819-27-3(Hazardous Substances Data)

Upstream product

• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Relevant articles and documents

Combining NMR and molecular modelling in a drug delivery context: Investigation of the multi-mode inclusion of a new NPY-5 antagonist bromobenzenesulfonamide into β-cyclodextrin

NMR spectroscopic and molecular modelling methods have been employed to describe the complexation of trans-N-4-[N′-(4-chlorobenzoyl) hydrazinocarbonyl]cyclohexylmethyl-4-bromobenzenesulfonamide, a new chemotype of NPY-5 antagonist, and β-cyclodextrin, rev

Novel human neuropeptide Y Y5 receptor antagonists for the treatment of obesity: Synthesis and biological evaluation of pyridine hydrazide derivatives

A series of new pyridine hydrazide derivatives with high and selective antagonist activity at the human neuropeptide Y Y5 receptor were developed. Introduction of electron-withdrawing groups into the arylsulfonamide rest, together with the 3-py

Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y 5 receptor antagonists for the treatment of obesity

NPY is the most potent orexigenic peptide identified up to now. Stimulation of food intake is measured by the Y1 and Y5 receptor subtypes. In this study, the synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives are described as potential selective antagonists of the human NPY Y5 receptor. The SAR of these series was examined and the amide derivatives were the compounds that showed the best activities. trans-N-{4-[(Quinolin-3-yl)aminocarbonyl]cyclohexylmethyl}- 2,4-dichlorobenzenesulfonamide (42) bound to the human neuropeptide Y Y 5 receptor with a 2 nM IC50.